Comprehensive research guide to metabolic peptides MOTS-c, AOD-9604, and Tesamorelin. Mechanisms of action, insulin sensitivity, mitochondrial function, and visceral fat metabolism with PubMed citations.
Last updated Aug 7, 2026·11 min read
When metabolic control fails, it fails in a chain. Insulin resistance invites high blood sugar. High sugar drives bad lipids. Bad lipids speed plaque in arteries. The World Health Organization estimates this now touches more than 20% of adults worldwide.
Old drugs fight one pathway at a time. Statins for cholesterol. Metformin for sugar. Fibrates for triglycerides. Peptides work differently. They can shift whole signaling chains at once across liver, muscle, fat, pancreas, and brain.
This guide follows three research peptides. Each works at a different level.
**MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity ** is a 16-amino-acid peptide built from mitochondrial DNA. It flips the AMPK pathway — the cell's main fuel switch, which runs sugar uptake, fat burning, and mitochondria growth PMID: 25533968 . **AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis ** is a made-made piece of growth hormone (parts 177–191). It breaks down fat through β3-adrenergic receptors and leaves IGF-1 alone PMID: 11739441 . **Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation ** is the only FDA-approved one here. It is a lab copy of GHRH that shrinks deep belly fat and helps liver fat and lipids PMID: 20101189 .
Read together, they show where peptide science goes. Metabolic trouble is not one fault. It is a web — fuel sensing inside cells, fat handling in fat cells, and hormone signals.
By the end, you will know each compound's story, how it works, how strong the proof is, and where the gaps are. This guide uses preclinical and clinical studies — not advice for human use, treatment, or diagnosis.
Start at the deepest level: inside the mitochondrion.
I.Overview
Metabolic control spans organs. The liver runs sugar output and fat build. Muscle clears most sugar. Fat tissue stores and releases fatty acids on hormone orders. The pancreas leads with insulin and glucagon.
Peptide work maps onto this chain at three levels — and the level sets both chance and risk.
1. Inside the cell (AMPK activation) — the floor. AMP-activated protein kinase is the cell's fuel gauge. When ATP drops from exercise or fasting, AMPK turns on fuel-making and shuts off fuel-using. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity , a peptide from mitochondria, moves to the nucleus under stress and flips AMPK on — possibly echoing parts of exercise PMID: 25533968 .
2. In the fat cell (β3-adrenergic path) — the fat level. Some peptides skip whole-body sensing and talk to fat cells direct. AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis breaks down fat by raising fat-cell response to catecholamines via β3-adrenergic receptors. Stored triglycerides leave without touching the GH receptor or IGF-1 PMID: 11739441 .
3. In the endocrine system (GHRH signaling) — the hormone level. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation starts pulses of the body's own GH, which favors belly fat loss. GHRH copies keep normal pulse timing instead of constant GH, so they may avoid some GH side effects PMID: 20101189 .
Level is the key idea. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity changes how single cells use fuel. AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis empties fat cells direct. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation steers a hormone chain that touches every tissue. Each level answers a different research question — cell efficiency, fat supply, hormone tone. That is why mixing them gets hard fast, as the synergy section shows.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity (Mitochondrial ORF of the Twelve S c) broke a textbook rule. This 16-amino-acid peptide sits in the 12S rRNA gene of mitochondrial DNA. Changhan David Lee's group at USC found it in 2015 — and it proved mitochondria DNA does more than build electron transport. It also builds signaling peptides that talk back to the nucleusPMID: 25533968 .
That find opened a new field: mitochondrial-derived peptides (MDPs). MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity and humanin lead it. For a molecule unknown a decade ago, its paper record grew fast.
The main move is AMPK activation, and the picture writes itself. When cell energy drops — from exercise, fasting, or stress — MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity leaves the mitochondrion, enters the nucleus, and flips the AMP-activated protein kinase switch PMID: 25565208 : the fuel gauge that turns on fuel-making and shuts off fuel-use.
Down the line, the chain reads like an exercise plan: more glucose uptake via GLUT4 moving to the cell wall, more fat burning, less fat build, mTOR cut — the build path that stores fat when over-run.
The first mouse studies gave proof. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity stopped diet-fed obesity and improved sugar tolerance without cutting food intake — the effect was pure metabolism, not appetite PMID: 25533968 . Later work held up: better metabolic balance and less insulin resistance in diet-fed obese mice, touching sugar and fat at once PMID: 25738459 .
Exercise mix is the liveliest edge. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity rises in muscle after activity, and work hints at real teamwork: the peptide engages exercise-set control of PGC-1α, easing insulin resistance and helping sugar use via AMPK PMID: 33288600 . A 2022 study found MOTS-c rises with long-term training and even helps single-dose exercise output PMID: 35929232 — hence the "exercise mimetic" tag, though the data points to working with exercise, not replacing it. Put plain: a runner's muscles already run this code.
New finds widen past classic metabolic syndrome. A 2025 study in Experimental & Molecular Medicine reports MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity stops pancreatic islet cell aging, possibly delaying diabetes by a path that skips insulin sensitivity [Nature 2025]. Another 2025 paper shows it fights diabetic liver scarring via the Keap1-Nrf2-Smad2/3 chain PMID: 40425777 — guard signals across many metabolic disease paths.
One cap covers all: near-zero human clinical data. Every efficacy result so far is from animals or cells. Rodent-to-human shift in metabolism is famously shaky, and MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity 's minutes-long half-life raises real bioavailability doubts for any clinic use.
Next: the compound that tried to keep growth hormone's fat burn while dropping its baggage.
AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis is an exercise in cutting. Take human growth hormone's 191 amino acids, keep only the tail — parts 177–191, plus a swap at spot 176 — and drop the rest. Frank Ng's group at Monash University set the rule: the fat-breaking work of GH lives in this piece, while growth and sugar effects sit elsewhere PMID: 11739441 .
The pitch is clean. Full-length growth hormone frees fat well but drags IGF-1 rise, insulin resistance, and acromegaly risk behind it. Keep just the fat signal and the gain column stays clear.
How it works: AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis breaks down fat by raising fat-cell response to catecholamines via β3-adrenergic receptors, mostly set on white fat. Down the line, hormone-sensitive lipase (HSL) and perilipin split lipid drops, freeing fatty acids from stored triglycerides PMID: 11739441 .
A 2001 knockout-mouse study tightened the tale. Obese mice given full-length GH or AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis raised β3-adrenergic receptor RNA to lean levels. In β3-AR knockout mice, long treatment changed neither weight nor fat loss — proving the receptor's key role. Yet in short tests AOD-9604 still lifted fuel burn in knockouts, hinting at a second, non-β3 path PMID: 11713213 .
Metabolic clean is the claim that sets it apart. Across preclinical work, AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis did not raise blood sugar, insulin, or IGF-1 PMID: 11739441 , showing the split from full-length GH. It also caused no insulin resistance in any study — a sharp contrast, since GH-led insulin resistance is among the worst side effects of GH therapy.
Human proof, though, cooled fast. A Phase 2 trial in 300 obese adults ran 12 weeks: the top dose (1 mg/day) beat placebo for weight loss — small in size. A later 24-week trial in 536 people then failed to repeat the result under strict diet-and-exercise and work stopped in 2007 [PMC3584306]. No Phase 3 followed.
One footnote matters for dope checks: a 2015 study mapped AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis 's in-vitro profile for anti-doping use — WADA bans it as a possible performance aid PMID: 25208511 .
A clean mechanism, a stalled clinic run — the exact flip of the compound next.
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation is the only one here that finished the race. This lab copy of growth hormone-releasing hormone, 44 amino acids long, won FDA approval in 2010 as Egrifta. It trims deep belly fat in HIV patients with fat-loss disorder PMID: 20101189 — full Phase 3 trials, after-market watch, and a set safety record. No other peptide here can say that.
Context helps: HIV drug therapy shifts fat hard — piling visceral fat into the gut while face and limbs thin. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's approval hit exactly that group: narrow, clear, and odd in metabolism.
The move runs the classic GH line. Binding GHRH receptors on pituitary cells lifts cAMP and starts pulse GH release. GH then drives liver IGF-1 output, feeding muscle, bone, and fat. In fat, GH starts fat loss — lifting hormone-sensitive lipase, raising catecholamine response, and pushing fatty acid burn. Belly fat answers more than subcutaneous fat, so the effect lands in belly VAT PMID: 20101189 .
Numbers from the key Phase 3: 412 HIV-positive patients with extra belly fat, split to tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 2 mg or placebo for 26 weeks. Result — belly fat down about 18%, subcutaneous fat near untouched, waist down 3.4 cm on mean PMID: 20101189 . Targeted shrink, not general weight loss.
Liver work got its own trial: in 48 HIV patients, six months cut VAT by 42 cm² and liver fat by 2.0% in the lipid-to-water ratio (P = .003). Fasting sugar spiked short at two weeks, then set by month six PMID: 25038357 .
Past HIV, a random trial in obese folk with low GH showed better body build and less trunk fat — with metabolic shifts like those in HIV [PMC3513535]. A 2026 meta-run of five RCTs set the record: VAT −27.71 cm², trunk fat −1.18 kg, liver fat −4.28%, waist −1.61 cm, plus the expected IGF-1 lift PMID: 41545261 .
Glucose is the watch-item. Short tests showed little insulin shift, and a 2017 trial in type 2 diabetes found tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation safe here but with no big sugar gain — GH-run metabolism is complex and does not auto-fix blood sugar PMID: 28630297 .
From a proven drug back to the research edge: what happens when three levels try to work as one?
fat-loss metabolic-health muscle-growth
III.How They Work Together
Three compounds, three levels — and the real question is whether the levels fit.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity works inside the cell: AMPK flips each cell toward burn mode — more GLUT4 glucose uptake, more fatty acid burn, less fat build, mTOR dialed down. The effects sit in each cell and add up to tissue gain: muscle burns more fat, liver sends out less sugar, fat cells bank less triglyceride PMID: 25533968 .
AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis works in the fat cell: β3-adrenergic input frees stored triglyceride without touching appetite, insulin, or GH — a side route, clear of the brain PMID: 11739441 .
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation works in the hormone system: a body-wide GH/IGF-1 chain hitting many organs at once, belly fat as the key aim, IGF-1 lift riding along PMID: 20101189 .
Set side by side, the three line up: AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis frees fat from store, MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity steers cells to burn what left, Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation strips belly fat via a whole other hormone route. Touch cell fuel sensing, fat-cell release, and hormone control at once — and in theory you get effects no single one gives alone.
Theory is where it stops. No controlled test has run any mix of these three — in any species. The most-studied peptide pair, CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue plus Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue , stays in one family (both GH-axis agents). Cross-level mixes stay untested.
Safety adds friction too: Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's GH link brings IGF-1 rise that AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis and MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity lack. Mixing it with others could boost GH-linked effects — insulin resistance, fluid hold, joint ache — in ways single-run tests cannot call. That doubt is a real wall to mix research, not a footnote.
So the practical take is careful humility: three moves proven at their own levels, zero proven teams. Before mix talk comes the plain layer — routes, doses, times — set out next.
IV.Frequently Asked Questions
Frequently Asked Questions
The split is one of focus, not stuff. Weight loss peptides are run mostly for their effect on body weight and fat mass — the out is a number on a scale. Metabolic peptides are run for their effect on the base work that steers energy metabolism — insulin response, sugar balance, lipid marks, cell power, and fat spread. Some sit in both: MOTS-c and AOD-9604 touch body build and metabolic marks. The metabolic peptide guide puts the how and the health side first, not weight loss gains.
AMPK (AMP-activated protein kinase) is the cell's fuel sensor. It fires when ATP drops. MOTS-c, a peptide from mitochondria, moves from the mitochondria to the nucleus under metabolic stress and flips AMPK on [PMID: 25565208]. AMPK lift raises glucose uptake via GLUT4 moving to the cell wall, adds fat burn, cuts fat build (new fat made), and holds mTOR (a build path). This chain turns cell metabolism from store to burn. In animals, this stopped diet-fed obesity without cutting food [PMID: 25533968]. The health link: weak AMPK signaling ties to insulin resistance, type 2 diabetes, and fatty liver disease.
The main proof is from Monash's lab work. In obese mouse models, AOD-9604 cut body fat without lifting blood sugar, insulin, or IGF-1 — showing the split from full-length GH [PMID: 11739441]. The move uses β3-adrenergic receptors on fat cells, not the GH receptor. A 2001 test showed AOD-9604 lifts β3-AR RNA in obese mice to lean levels, and β3-AR knockout mice show no long-run reply to AOD-9604 [PMID: 11713213]. Still, human data holds only one Phase 2 trial (n=300, 12 weeks) with small gains, and a later 24-week test that failed to repeat the find.
Belly fat seems to answer GH-led fat loss best. Belly fat holds more GH receptors and hormone-sensitive lipase than side fat. Also, belly fat drains straight to the portal line, so its drop brings fast gain — fewer free fatty acids at the liver, better liver insulin response, and less triglyceride build. In the key Phase 3, tesamorelin cut belly fat about 18% with little side-fat change [PMID: 20101189]. A 2026 meta-run of five RCTs set drops of 27.71 cm² in belly fat and 4.28% in liver fat [PMID: 41545261].
Proof differs by compound. MOTS-c has the strongest lab proof — it lifted sugar tolerance and cut insulin resistance in diet-fed obese models without cutting food [PMID: 25533968], and a 2025 test shows it stops pancreatic islet cell aging [Nature 2025]. AOD-9604 caused no insulin resistance in any test, but its gain in insulin response has not been shown direct. Tesamorelin's sugar effects run complex: a 2017 test in type 2 diabetes found it safe with no big sugar gain [PMID: 28630297]. The solid human proof of metabolic gain sits in tesamorelin's liver fat cut — liver fat is a known driver of liver insulin resistance.
No set tests of these exact mixes exist. The pitch is fair: GLP-1 drugs cut appetite and lift insulin output in the brain, while metabolic peptides hit other paths — AMPK (MOTS-c), direct fat free (AOD-9604), and GH-led belly fat cut (tesamorelin). Still, mix safety data is gone. Tesamorelin's IGF-1 lift could meet GLP-1 drug effects on insulin in ways we cannot call. Any mix work would need tight drug-path and safety checks.
Metformin works mostly by firing AMPK in a side way — it blocks mitochondrial complex I, which raises the AMP:ATP ratio. MOTS-c fires AMPK by another route (move to the nucleus and gene control). AOD-9604 and tesamorelin run on whole other paths (β3-adrenergic and GH/IGF-1) with no meet with metformin. The core split: set metabolic drugs are approved, well-mapped, and hold decades of safety record. Metabolic peptides are lab compounds with thin human data, and none are approved for metabolic use beyond tesamorelin's HIV fat-loss sign.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity , AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis , and Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation are three answers to one ask — how to step into metabolism — at three biological levels: inside-cell fuel sensing (AMPK), fat-cell fat release (β3-AR), and body-wide hormone control (GH axis).
Set: each works in its own lane. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity flips AMPK and stops diet-fed obesity in animals PMID: 25533968 ; AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis frees fat via β3-adrenergic receptors without lifting IGF-1 PMID: 11739441 ; Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation cuts belly and liver fat in set human tests as the trio's only FDA-approved one PMID: 20101189 .
Not set: whether these three mix safe or strong, whether rodent gains hold in humans, or whether metabolic peptides can reach spots of metabolic syndrome that old drugs miss.
One line gets the last word: weight loss and metabolic health are not the same word. GLP-1 receptor agonists win the scale race in this guide by far — yet cell power, belly fat spread, and liver fat are targets that appetite-cut drugs do not hit direct. Whether that shelf becomes clinic gain is the open ask.
Go on with the Weight Loss Peptides guide for the scale side; compound pages sit at [MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity ](/en/compounds/mots-c/), [AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis ](/en/compounds/aod-9604/), and [Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation ](/en/compounds/tesamorelin/); head-to-heads at AOD-9604 vs MOTS-c and AOD-9604 vs Tesamorelin; source papers via PubMed.
Whichever level calls you most, you now hold the map of all three.
AOD-9604 
MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity (Mitochondrial ORF of the Twelve S c) broke a textbook rule. This 16-amino-acid peptide sits in the 12S rRNA gene of mitochondrial DNA. Changhan David Lee's group at USC found it in 2015 — and it proved mitochondria DNA does more than build electron transport. It also builds signaling peptides that talk back to the nucleus PMID: 25533968 .
CJC-1295 
Ipamorelin